Pharmaceuticals

The Michael J. Fox Foundation and Parkinson’s UK award $5.2 million to Mission Therapeutics to research potential treatments for Parkinson’s disease

bexib
By bexib 0 Min Read

MTX325 is in Phase I trials and is thought to be able to alter the course of the disease.

You Might Also Like

To overcome barriers, cell and gene therapy needs outside help

Deerfield Agency Acquires Embedded to Launch New Life Sciences Marketing Brand

Pharma Pulse 5/30/24: Strategies for conducting strong and efficient peer review of research papers, the arrival of smart bandages, and more

FDA Grants Premarket Approval to Endotronics’ Cordella Pulmonary Artery Sensor System to Support Heart Failure Patients

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

Share This Article
Previous Article Bitcoin Plummets to $57K, Solana Plummets 8% in One Day (MarketWatch) – Investorempires.com
Next Article Nigeria plans to develop research centre focusing on blockchain and emerging technologies – Investorempires.com
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

How eSIM, IoT and connectivity security are driving Industry 4.0
Manufacturing
Blue Dart opens India’s largest integrated operations facility in Bijwasan, Delhi
Manufacturing
AOKI Mobility launches cutting-edge electric bicycle that realizes sustainable urban transportation
Manufacturing
Taiwan Excellence to showcase next-generation metal processing solutions at IMTEX 2025
Manufacturing